dissemination – Page 55 – Communicable Diseases Research

Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-10-272022-10-29
Journal: Trials [Category] COVID-19, MERS, SARS,

The efficacy of Siddha Medicine, Kabasura Kudineer (KSK) compared to Vitamin C & Zinc (CZ) supplementation in the management of asymptomatic COVID-19 cases: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-10-272022-10-29
Journal: Trials [Category] Coronavirus, MERS, SARS,

[키워드] 1:1 accompany addition adverse effect Asymptomatic Asymptomatic COVID-19 baseline blinded breathlessness bronchial asthma calculated carried Chain Reaction changes in Chennai clinical clinical assessment clinical trial co-morbidity college control group cough COVID COVID-19 CTRI Data analysis determine Diabetes Mellitus dissemination dose Efficacy element eligibility assessment evaluate excluded exploratory Factor Fever filtered Herbal decoction hypertension IFNγ IL10 IL2 Immunity immunological independent India information investigator involved lactating malignancy management marker Medicine Microsoft Excel number objective Occurrence onset of symptom Open-label outcome parallel group participant positive pregnant Primary outcome progression protocol random number generation randomised randomised controlled trial randomization Randomized controlled trial receive recruit recruited recruitment reduced reducing reduction reduction in Registered reported RT-PCR Sample Sample size SARS-CoV-2 viral load sealed Secondary outcomes severe respiratory disease Siddha Siddha Medicine Standard state Study protocol submitted Symptom symptomatic Tablet tested the SARS-CoV-2 threshold TNF traditional methods Treatment Trial Tumor Vitamin website Zinc
[DOI] 10.1186/s13063-020-04823-z PMC 바로가기 [Article Type] Letter

Investigating the Prevalence of Reactive Online Searching in the COVID-19 Pandemic: Infoveillance Study

Original Paper

Published on 2020-10-272022-10-30
Journal: Journal of Medical Internet Research [Category] COVID-19, MERS, SARS,

[키워드] addressed affected age being Care carried Chloroquine circulation coronavirus correlation Correlation analysis country COVID-19 COVID-19 pandemic COVID-19 testing death determine disease dissemination European fake news Germany global pandemic Google Google Trends Government Health ibuprofen identify imperative infodemiology information Italy limit maintain media misinformation Mortality mortality data objective pandemic Pandemics Panic portal positive correlation powerful tool Premature Public public health authorities resources Result resulting searched selected Spain Spearman Spread Strong temporal dynamics The United States trend United Kingdom Volume
[DOI] 10.2196/19791 PMC 바로가기 [Article Type] Original Paper

Evaluation of the efficacy and safety of Melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial

중등도의 COVID-19 환자에서 멜라토닌의 효능 및 안전성 평가: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-10-262022-08-13
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] 1:1 acute respiratory syndrome Adverse drug reaction Adverse drug reactions alcohol All study participants allergy allocation sequence Alpha anticipated Antiviral Arm ARMS assigned Bandar Abbas blinded Blinding block randomization Breastfeeding C-reactive protein Chain Reaction chronic hepatitis cirrhosis clinical clinical symptom Clinical symptoms clinical trials Clinicians Computed tomography conducted Confirmed Control control group Corticosteroids COVID-19 COVID-19 pneumonia criteria Critical Department Depression diabetes Diabetes Mellitus Diagnosis Diseases dissemination dose double-blind drug drugs education Efficacy and safety element evaluate exclusion criteria faculty feature generate Hepatitis history Hospitalization Hospitalized hypertension IL-1β IL-6 ill patient IMPROVE incidence inclusion criteria inflammatory parameter inflammatory parameters Inflammatory responses Informed consent interleukin interleukin-1β Iran liver diseases Medical Sciences Medicines melatonin Ministry of Health number Nurses objective outcome oxygen oxygen saturation parallel-group participant Participants Patient patients patients randomized pharmaceutical Pharmacy Placebo placebo-controlled clinical trial Pneumonia polymerase chain polymerase chain reaction polymerase chain reaction) positive Pregnancy Primary outcome Primary outcomes protocol random randomization Randomized Randomized controlled trial regimen Registered registration date registration number registry Research respiratory Sample size SARS-CoV-2 screened secondary outcome Secondary outcomes Seizure serum Seven Severe acute respiratory syndrome single-center standard treatment status Study protocol the Faculty therapeutic treatment arm trial protocol Trial registration Tumor tumor necrosis tumor necrosis factor tumor necrosis factor-alpha two group two groups underlying diseases university Version Warfarin web-based system website X-ray
[DOI] 10.1186/s13063-020-04737-w PMC 바로가기 [Article Type] Letter

BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial

COVID-19에 대한 타고난 면역 반응을 개선하기 위해 브라질에서 의료 종사자의 BCG 재접종: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-10-262022-08-13
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] accompany activate acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 Admission Antibiotics antiviral immune response approved assigned Autoimmune Autoimmune diseases Bacillus BCG BCG revaccination BCG vaccination bcg vaccine blinded Blinding block blocks both groups Brazil Breastfeeding carried CFU Characteristics Chemotherapy childhood city clinical trial Committee Comorbidities Comorbidity confirmation Contact contact with control group Coronavirus-2 COVID-19 COVID-19 patient COVID-19 severity COVID-19 symptoms COVID-19 test cross-protection determined by diagnosed direct contact disease disease severity Diseases dissemination dose doses Effectiveness element elicited eligibility criteria Fever health worker health workers healthcare providers HIV hospital Hypothesis ICU identification number IgG and IgM IgM and IgG IgM test immunosuppressive IMPROVE in both group incidence incidence of COVID-19 Inclusion inclusion criteria India induce Infection infections information innate immune response investigator Laboratory lateral flow less macrophages medication meet memory monocyte Monocytes Mortality naso-oropharyngeal swab neutrophil Neutrophils NK NK cell number Nurses objective Open-label outcome outcomes pandemic parallel-group participant physiotherapists platform presenting Prevent Primary outcome Primary outcomes professional protocol randomisation randomised randomised controlled trial randomization Randomized receive recruit recruitment reduce Registered registration number researcher researchers respiratory revaccination right arm RT-PCR Sample size SARS-CoV-2 scar sealed Secondary objective Secondary objectives secondary outcome severe acute respiratory syndrome Coronavirus severity solid tumour specimen statistical analyses status steroid Study protocol Symptom symptomatic infection the disease the vaccine Trial Trial registration Tuberculosis two groups vaccination Vaccine virus virus infection virus infections was performed website WHO
[DOI] 10.1186/s13063-020-04822-0 PMC 바로가기 [Article Type] Letter

An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial

Letter

Published on 2020-10-262022-10-29
Journal: Trials [Category] COVID-19, MERS, SARS,

[키워드] 1:1 accompany Admission age alcohol allocation concealment ALT/AST Arm assigned Beta block-randomization Blood body temperature Care clinical Clinical improvement clinical trial comparator Confirmed control group COVID COVID-19 COVID-2019 CT scan death discharge disease dissemination drug duration of hospitalization Effect Effectiveness element eligibility criteria exclusion criteria fatigue group headache Health High dose High-dose hospital hospital discharge Hospitalization improvement incidence include Infection information Interaction interferon beta Interferon beta-1a Interferon-β 1a intervention group Intubated Invasive mechanical ventilation investigator Kaletra Laboratory results lactating women Last less limit Loghman Hakim Hospital Lopinavir/ritonavir low dose low-dose masking mechanical ventilation Medical Sciences moderate Mortality nasal Non-invasive number objective open label Open-label outcome oxygen saturation oxygen support package parallel group participant Patient pregnant Primary outcome primary outcome measure professional protocol R software Radiation randomised randomization randomization sequence Randomized Randomized controlled trial Randomly receive Recigen recruitment refusal regimen Registered Research respiratory rate Ritonavir RT-PCR RT-PCR test Sample size SARS-CoV-2 sealed secondary secondary outcome seven-category ordinal scale severe disease Shortness of breath single center standard care status Study protocol Symptom the patient therapeutic time treated treatment groups Trial two groups university version 3.6.1 website World Health Organization
[DOI] 10.1186/s13063-020-04812-2 PMC 바로가기 [Article Type] Letter

Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial

중증 COVID-19 환자의 회복기 혈장 수혈 요법- 안전성, 효능 및 용량 반응 연구: 2상 무작위 대조 시험 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-10-262022-08-13
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] (neutrophil 24 hour 24 hours allergic allergic reaction Antibody titre Arm ARMS automated blinded Blinding body temperature BSMMU Care checked Clinical improvement collaboration collected comparator computer Controlled Controlled trial convalescent plasma COVID-19 creatinine criteria CRP CT scan deaths defined diastolic discharge dissemination Donor donors dose dose response effective effective dose Efficacy Efficacy and safety element ELISA end point enrolled Evidence evidence of excluded expected FiO2 generate Health Organization hospital Hospital stay ICU identify in-hospital mortality inclusion criteria initial intervention arms Laboratory laboratory parameter Laboratory parameters Laboratory tests lactating women lung lymphocyte multi-arm multicentre neutralizing antibody neutrophil normality number objective open outcome Oxford oxygen oxygen saturations PaO2 paO2/fiO2 participant Participants Patient PCR assay performed plasma Plasma transfusion positive pregnant Primary outcome proportion protocol random number table randomised Randomized controlled trial RCT receive recorded recording recruit recruited recruitment reduction in required respiratory respiratory distress respiratory rate respiratory symptoms room air RT-PCR RT-PCR assay Sample size sample size calculation SARS-CoV-2 secondary outcome serum creatinine Serum ferritin Seven Severe case severe cases severe COVID-19 severe COVID-19 patient severe COVID-19 patients Severe patient severe patients Severe respiratory distress Sex SGOT SGPT SpO2 sputum standard care status Study protocol Support systolic the patient therapy These data titre transfusion Treatment Trial university University of Oxford ventilator website World Health Organization X-ray
[DOI] 10.1186/s13063-020-04734-z PMC 바로가기 [Article Type] Letter

“Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial”

Letter

Published on 2020-10-222022-10-29
Journal: Trials [Category] COVID-19, MERS, SARS,

[키워드] 1:1 ABO accompany addition Adult patient adverse event age anti-SARS-CoV-2 antibody Antibody titer anticipated blood product Cardiopulmonary CCP CDC Comorbidities Comorbidity conducted convalescent plasma COVID-19 COVID-19 pneumonia patient criteria decrease Decreased defined disease dissemination dose elderly element eligible for inclusion hospital Identifier IgA increase Increased information investigator IRCCS Italy Length life-threatening Nasopharyngeal swab number objective older patient Open-label outcome paO2/fiO2 parallel group participant Patient performed phase plasma Pneumonia positive Prevent proceed progression protocol pulmonary disease randomised randomised controlled randomised controlled trial Randomized receive recipients recruitment refusal Registered risk SAE Sample size SARS-CoV2 secondary Secondary objective sequence severe pneumonia severity Sex Standard Standard therapy status Stratification Study protocol the patient therapy titre Total Trial two-tailed Viral load Viremia website WHO with COVID-19 worsening
[DOI] 10.1186/s13063-020-04821-1 PMC 바로가기 [Article Type] Letter

COVID-19 Self-Reported Symptom Tracking Programs in the United States: Framework Synthesis

Original Paper

Published on 2020-10-222022-10-30
Journal: Journal of Medical Internet Research [Category] COVID-19, MERS, SARS,

[키워드] age Care Cluster collected coordination coronavirus COVID-19 COVID-19 symptom cross dissemination duplication effective effort elements evaluate Final for inclusion framework Framework analysis Gender Health inclusion criteria individual infected individual Infection information information resources knowledge Local Mental monitoring objective outbreak pandemic participant Patient-reported outcome measures presenting Program public health Research researcher responses Result School Schools screened self-reported smoking status spread of COVID-19 Surveillance Symptom symptom tracking synthesis the United State The United States threshold turn
[DOI] 10.2196/23297 PMC 바로가기 [Article Type] Original Paper

The clinical effect of Nano micelles containing curcumin as a therapeutic supplement in patients with COVID-19 and the immune responses balance changes following treatment: A structured summary of a study protocol for a randomised controlled trial

COVID-19 환자의 치료 보조제로 커큐민을 함유한 나노 미셀의 임상 효과 및 치료 후 면역 반응 균형 변화: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-10-222022-08-13
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] 1:1 accompany addition allergy assigned balance Bandar Abbas bedtime blind Blinding both groups breakfast Capsule change Characteristics chronic chronic obstructive pulmonary disease clinical Clinical effect clinical examination clinical examinations clinical symptom clinical trial clinical trials Comorbidities Comorbidity company comparator Complete computer conducted congestive heart failure control group COVID-19 COVID-19 patient COVID-19 patients Curcumin Cytokines digit digits dinner dissemination Effectiveness element evaluate evaluated expected expression filtration filtration rate FOXP3 gallstone gastritis GATA Gender Gene Expression glomerular filtration rate heart failure history IFN-γ IL-17 IL-4 immune response immune responses in both group inclusion criteria Inflammatory marker inflammatory markers information Interleukins intervention group Iran kPa Laboratory laboratory findings laboratory technician laboratory technicians lactation less liver liver failure Lymphocytes number Nurses objective Obstructive obstructive pulmonary disease outcome PaO2 parallel group participant Participation Patient patients patients with COVID-19 per day performed Peripheral blood physician Placebo placebo group placebo-controlled positive COVID-19 post treatment Pregnancy protocol pulmonary disease random randomisation randomised randomised controlled trial randomization Randomized randomized clinical trial Randomly real time PCR recorded recruitment Registered registry Regulatory renal renal failure routine standard treatment Sample size sealed selected serum cytokine serum cytokines Serum level serum parameter serum parameters shift single-center statisticians Study protocol T helper TGF-β the placebo group therapeutic Treatment Trial Trial registration ventilator Version website written consent
[DOI] 10.1186/s13063-020-04824-y PMC 바로가기 [Article Type] Letter